GlaxoSmithKline (GSK), Bayer (BAYRY) Eyeing Potential In CRISPR Therapeutics (CRSP); Intersections’ (INTX) Segment Attracts Interest

crispr_therapeutics_crsp

After the closing-bell Friday, British drug giant GlaxoSmithKline plc (NYSE:GSK) disclosed in a regulatory filing ( SC 13D ) with the U.S. Securities and Exchange Commission (SEC) an 8.3% stake (3,250,627 shares) in CRISPR Therapeutics AG (Nasdaq:CRSP), while Bayer Global Investments B.V. – a subsidiary of German chemical and pharma giant Bayer AG (OTCMKTS:BAYRY) – disclosed to the Federal agency ( SC 13D ) a 12.8% stake (5,105,330 shares) in the gene-editing company.

CRSP stock finished the regular session in positive territory by 5.82% (or +0.92) at $16.74, with a total volume of 119,730 shares traded

CRISPR Therapeutics, which focuses on the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 gene-editing platform, has 39.36M Shares Outstanding and Market Capitalization (intraday) of $658.90M. CRSP stock range – since its debut as a public company in October 19, 2016 – is between $13.75 and $17.49 per share

*

intersections_intx

Intersections Inc. (Nasdaq:INTX) shares climbed more than 12% in after-hours trading Friday as the company said that it received a letter with a non-binding proposal from its largest stockholder – Loeb Holding Corp. – to acquire its Pet Health Monitoring Segment

According to Intersections, a Special Committee will evaluate the proposal, but said there is no certainty a deal will be reached

INTX stock closed at $1.76, up $0.01 (or +0.57%), and 2,460 of its shares changed hands during the day, representing a decrease in activity versus its average volume (3m) of 12,880

Intersections, which provides subscription based services to manage personal information and risks, has 23.68M Shares Outstanding, Market Capitalization (intraday) of $41.68M and INTX stock 52-week range is from $1.70 to $3.55 per share

**

Disclaimer: The disclaimer is to be read and fully understood before using our site, or joining our email list. GalaxyStocks is not a registered investment adviser. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Investors should always conduct their own due diligence with any potential investment, with independent research and other professional advice. Read full disclaimer at http://galaxystocks.com/disclaimer/